![]() |
Xigris: A Worldwide Withdrawal...
January 1, 2012 - Clinical , In the News / Politics By: Khilna Patel, Pharm.D. Candidate c/o 2012 – On October 25 of this year, Eli Lilly and Company announced a worldwide market withdrawal of Xigris (drotrecogin alfa), a drug previously indicated to treat severe sepsis in high-risk patients. Drotrecogin alfa is a recombinant form of human activated protein C. The efficacy of drotrecogin alfa was… |
![]() |
Stool Transplants in C. difficile Infections...
December 1, 2011 - Clinical , Featured By Ebey P. Soman – Many living organisms occupy our intestines to aid us with metabolism, recycling of hormones, and, most importantly, protection against foreign pathogens. When this normal flora of bacteria is altered or eliminated via antibiotic use, there is an opportunity for Clostridium difficile to infect us. Stool transplant, or fecal bacteriotherapy, is… |
![]() |
A Day in the Life of a Cardiac Care Unit Pharmacist...
December 1, 2011 - Professional Advice / Opinions By: Dr. Manouchkathe Cassagnol – Dr. Manouchkathe Cassagnol is an Assistant Clinical Professor at St. John’s University College of Pharmacy and Allied Health Professions and a Clinical Coordinator of Internal Medicine and Cardiology Pharmacotherapy at Long Island Jewish Medical Center. About 81 million people in this country suffer from cardiovascular disease. Therefore, as pharmacy practitioners,… |
![]() |
Differences Between Antagonists and Inverse Agonists...
December 1, 2011 - Clinical By: Neal Shah – There are two major classifications of drug-receptor activity: agonism and antagonism. Agonism occurs when a molecule binds to a receptor, causes an exertion of normal receptor operation, and eventually causes a response. Antagonism of a receptor occurs when a molecule binds to the receptor and does not allow activity to occur.1… |
![]() |
Ivabradine: A Novel I(f) Blocker for Stable Angina...
December 1, 2011 - Clinical By: Neal Shah – Part I: Preface. Part II: Brief review of cardiac electrophysiology. Part III: Ivabradine as a novel If blocker for the use of stable angina. Part IV: On the horizon: trimetazidine. – PREFACE When viewed anatomically, the heart may seem like a simple organ. However, the electrophysiological aspects of the heart are… |
![]() |
Federal Government to Attempt Limiting Drug Shortages...
December 1, 2011 - In the News / Politics By: Mahdieh Danesh Yazdi, with special thanks to Dr. Tomasz Jodlowski – Drug shortages have plagued health care institutions in recent years; they present a serious problem to health care delivery on a national scale. In 2004, there were 58 drug shortages; now, in 2011, this number has increased to 198. Due to limited access… |
![]() |
Pharmacogenetic Applications in Clinical Practice...
November 1, 2011 - Clinical , Featured By: Neal Shah – The focus of pharmacy is rapidly shifting from simple filling and dispensing of prescriptions to preventative medicine and efficient clinical practice. The field of genetics has been incorporated in many defining therapies and will continue to shape how we treat our patients. Examples discussed here are the roles of human leukocyte… |
![]() |
In The News: TNF-Alpha Inhibitors Receive More Warnings...
October 1, 2011 - In the News / Politics By Ebey P. Soman – TNF-alpha inhibitors are drugs used to treat rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, as well as other disease states. These agents suppress the immune system and increase the risk of developing serious infections. Currently, there are five approved drugs in this category: • Adalimumab (Humira®, Abbott) • Certolizumab pegol… |
![]() |
Faculty Spotlight: Dr. Parnali Chatterjee...
October 1, 2011 - Featured , Professional Advice / Opinions By: Ebey P. Soman – Meet Dr. Parnali Chatterjee, a new faculty member in our St. John’s University family. I had the opportunity to meet Dr. Chatterjee at the doctoral seminar hosted by Dr. Lin Mantell entitled, “Drug Metabolism and Pharmacokinetics in Drug Discovery and Development.” I was introduced to Dr. Chatterjee through Dr. Frank… |
![]() |
The Industry: Generics Drugs and Intellectual Property ...
October 1, 2011 - Featured , Professional Advice / Opinions By: Ebey P. Soman – The World Trade Organization (WTO) and its member nations met in Uruguay in 1994 to establish international norms for trade, economy, and development. They developed the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which provided patent protection for pharmaceutical companies to make brand name medications and market those… |